Research Insights on Epithelial Ovarian Cancer - Pipeline Review, H2 2016
Epithelial Ovarian Cancer - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Epithelial Ovarian Cancer (Oncology) pipeline landscape.
Ovarian epithelial cancer is a disease in which malignant (cancer) cells form in the tissue covering the ovary. Early ovarian cancer may not cause any symptoms. When symptoms do appear, ovarian cancer is often advanced. Symptoms may include pain or swelling in the abdomen, pain in the pelvis and gastrointestinal problems, such as gas, bloating, or constipation. There are different types of treatment for patients with ovarian epithelial cancer such as surgery, radiation therapy, and chemotherapy.
To access full report with TOC, please visit Epithelial Ovarian Cancer - Pipeline Review, H2 2016
Report Highlights
This report provides comprehensive information on the therapeutics under development for Epithelial Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Epithelial Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Epithelial Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 11, 38, 23, 2, 11, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 3 and 3 molecules, respectively.Epithelial Ovarian Cancer.
Epithelial Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Epithelial Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Epithelial Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Epithelial Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Epithelial Ovarian Cancer (Oncology)
- The pipeline guide reviews pipeline therapeutics for Epithelial Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Epithelial Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Epithelial Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Epithelial Ovarian Cancer (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Epithelial Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Epithelial Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AbbVie Inc Adaptimmune Therapeutics Plc Amgen Inc Astex Pharmaceuticals Inc AstraZeneca Plc Atara Biotherapeutics Inc Bayer AG BioNumerik Pharmaceuticals Inc Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company Celldex Therapeutics Inc Celon Pharma Sp z oo Celsion Corp CerRx Inc Cerulean Pharma Inc Clovis Oncology Inc Dr. Reddy's Laboratories Ltd EirGenix Inc. Eisai Co Ltd Eli Lilly and Company Esperance Pharmaceuticals Inc Exelixis Inc F. Hoffmann-La Roche Ltd Gene Techno Science Co Ltd Genentech Inc Genor BioPharma Co Ltd Glycotope GmbH Ignyta Inc ImmunoGen Inc Incyte Corp Innate Immunotherapeutics Ltd Johnson & Johnson Juno Therapeutics Inc Mabion SA MabVax Therapeutics Holdings Inc Mateon Therapeutics Inc MedImmune LLC Merck & Co Inc Merck KGaA Mycenax Biotech Inc Novartis AG Novogen Ltd Oasmia Pharmaceutical AB OBI Pharma Inc Oncobiologics Inc Oncolix Inc Oncolytics Biotech Inc Oxford BioMedica Plc OXIS International, Inc. Pharma Mar SA Prima BioMed Ltd PsiOxus Therapeutics Ltd Rgenix Inc Richter Gedeon Nyrt Sanofi Sanofi Pasteur SA Shenzen SiBiono GeneTech Co., Ltd. Sotio as TapImmune Inc Tara Immuno-Oncology Therapeutics LLC Tesaro Inc TetraLogic Pharmaceuticals Tyrogenex Inc VentiRx Pharmaceuticals Inc Verastem Inc Vyriad Inc
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 08:43
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home